Skip to main
BHVN

BHVN Stock Forecast & Price Target

BHVN Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 30%
Buy 20%
Hold 40%
Sell 10%
Strong Sell 0%

Bulls say

Biohaven is a clinical-stage biopharmaceutical company with a deep pipeline spanning multiple therapeutic areas. The company's approach of targeting high unmet needs and utilizing innovative modalities, such as antibody degraders, creates multiple opportunities for potential success. While the company faces typical biotech risks and high capital outlays, its potential for market differentiation and a diverse pipeline make it an attractive investment opportunity with significant long-term potential.

Bears say

Biohaven is a clinical-stage biopharmaceutical company with a diverse product pipeline and current focus on treatments for neuromuscular, metabolic, and neurological disorders. However, the company faces potential challenges in ensuring access to its treatments and demonstrating differentiated efficacy and tolerability in a competitive market. While the company has several promising programs, it may take time for these to show meaningful commercial results and the early-stage nature of its pipeline poses a valuation risk. Additionally, Biohaven's degrader platform shows promise, but further clinical development is needed to demonstrate its potential.

BHVN has been analyzed by 10 analysts, with a consensus rating of Buy. 30% of analysts recommend a Strong Buy, 20% recommend Buy, 40% suggest Holding, 10% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Biohaven Pharmaceutical Hld and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Biohaven Pharmaceutical Hld (BHVN) Forecast

Analysts have given BHVN a Buy based on their latest research and market trends.

According to 10 analysts, BHVN has a Buy consensus rating as of Sep 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $15.70, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $15.70, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Biohaven Pharmaceutical Hld (BHVN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.